Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Teva Pharmaceutical Industries Ltd (TEVA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4,885 +55    +1.14%
- Closed. Currency in ILS ( Disclaimer )
Type:  Equity
Market:  Israel
ISIN:  IL0006290147 
S/N:  629014
  • Volume: 1,186,722
  • Bid/Ask: 0 / 0
  • Day's Range: 4,885 - 4,885
Teva 4,885 +55 +1.14%

TASE:TEVA Financials

 
A brief overview of the TASE:TEVA financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Teva Pharmaceutical Industries Ltd over time.

Teva Pharmaceutical Industries Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 15,846 million compared to USD 14,925 million a year ago. Net loss was USD 559 million compared to USD 2,446 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 2.2 a year ago. Diluted loss per share from continuing operations was USD 0.5 compared to USD 2.2 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

TEVA Income Statement

Gross margin TTM 48.25%
Operating margin TTM 20.07%
Net Profit margin TTM -3.53%
Return on Investment TTM 9.11%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 4457 3850 3878 3661
Gross Profit 2416 1851 1796 1582
Operating Income 1250 761 670 498
Net Income 429 80 -863 -205

TEVA Balance Sheet

Quick Ratio MRQ 0.54
Current Ratio MRQ 1.02
LT Debt to Equity MRQ 241.95%
Total Debt to Equity MRQ 270.09%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 43479 42088 43095 43456
Total Liabilities 35353 34577 35387 34845
Total Equity 8126 7511 7708 8611

TEVA Cash Flow Statement

Cash Flow/Share TTM 1.22
Revenue/Share TTM 14.14
Operating Cash Flow  9.67%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1184 5 324 -145
Cash From Investing Activities 301 184 302 181
Cash From Financing Activities -576 -576 -55 -706
Net Change in Cash 977 -420 494 -658
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TEVA Comments

Write your thoughts about Teva Pharmaceutical Industries Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ramba Łej
Kubizm May 30, 2023 5:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
did tave make to many pivots on 18th may that red color is still ongoing each time I check?
Avi Braun
Avi Braun Apr 10, 2023 9:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
85%
Ramba Łej
Kubizm Apr 10, 2023 9:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what do you mean by 85%?
Ramba Łej
Kubizm Nov 23, 2022 9:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
WTH! When JPMorgan says downgrade smth just f* it, its only JPMorgan not anyone worth listening to...
Ramba Łej
Kubizm Jun 02, 2022 3:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
while teva is within channel and have been moving horizontally, riseing volume is worth noticing. I think we are in well-advanced accumulation state. I hope teva will solve opioid bs and find its way to increase sales volume
Michael Shalom
Michael Shalom Nov 25, 2021 3:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
asdfasdfadf investing
Michael Shalom
Michael Shalom Nov 24, 2021 7:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
google <a href="https://www.google.com"> google </a>
TSahi Livnoni
TSahi Livnoni Oct 18, 2020 3:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nice move against nasdaq on last friday
SS SS
SS SS Apr 13, 2020 2:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hello Associates & Partners I sold at 10.45 $ and now I am looking to entry in NGM , MYOVANT or MERSANA what which is your impact and your opinion which equity will go better for short term? please if anybody knows let me know your precious feedback, Szilike.
Playing Best
Playing Best Mar 31, 2020 5:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good news. teva will sell malaria cure against the corrona virus
Sam Diamond
Sam Diamond Mar 31, 2020 5:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I personally know someone who used it and it worked very well. They are going to see some big volumes even if they have competition. When you're dealing with these quantities, everyone makes money.
test test
test test Mar 31, 2020 5:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yes
test test
test test Mar 31, 2020 5:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Vladi Pukin
Vladi Pukin Mar 31, 2020 5:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sam Diamond
Sam Diamond Mar 22, 2020 5:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when the Dow drops 900 points and Teva is up, that's a really good sign of strength.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email